Zhao et al. also found that RUNX1 mutants exhibited decreased transactivation activity as well as had a dominant-negative function on the WT-RUNX1 as a result of AML transformation in a subset of CML patients [20]. Here, RUNX1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.